Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial
- PMID: 8133537
- DOI: 10.1093/jnci/86.7.539
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial
Abstract
Background: Retinoids enhance differentiation of most epithelial tissues. Epidemiologic studies have shown an inverse relationship between dietary intake or serum levels of vitamin A and the development of cervical dysplasia and/or cervical cancer. Pilot and phase I investigations demonstrated the feasibility of the local delivery of all-trans-retinoic acid (RA) to the cervix using a collagen sponge insert and cervical cap. A phase II trial produced a clinical complete response rate of 50%.
Purpose: This randomized phase III trial was designed to determine whether topically applied RA reversed moderate cervical intraepithelial neoplasia (CIN) II or severe CIN.
Methods: Analyses were based on 301 women with CIN (moderate dysplasia, 151 women; severe dysplasia, 150 women), evaluated by serial colposcopy, Papanicolaou cytology, and cervical biopsy. Cervical caps with sponges containing either 1.0 mL of 0.372% beta-trans-RA or a placebo were inserted daily for 4 days when women entered the trial, and for 2 days at months 3 and 6. Patients receiving treatment and those receiving placebo were similar with respect to age, ethnicity, birth-control methods, histologic features of the endocervical biopsy specimen and koilocytotic atypia, and percentage of involvement of the cervix at study. Treatment effects were compared using Fisher's exact test and logistic regression methods. Side effects were recorded, and differences were compared using Fisher's exact test.
Results: RA increased the complete histologic regression rate of CIN II from 27% in the placebo group to 43% in the retinoic acid treatment group (P = .041). No treatment difference between the two arms was evident in the severe dysplasia group. More vaginal and vulvar side effects were seen in the patients receiving RA, but these effects were mild and reversible.
Conclusions: A short course of locally applied RA can reverse CIN II, but not more advanced dysplasia, with acceptable local side effects.
Implications: A derivative of vitamin A can reverse or suppress an epithelial preneoplasia, lending further support to the notion that chemoprevention of human cancer is feasible.
Comment in
-
Cervical dysplasia regression induced by all-trans-retinoic acid.J Natl Cancer Inst. 1994 Apr 6;86(7):476-7. doi: 10.1093/jnci/86.7.476. J Natl Cancer Inst. 1994. PMID: 8133526 No abstract available.
Similar articles
-
Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III.Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2148-52. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15598773 Clinical Trial.
-
Retinoids for preventing the progression of cervical intra-epithelial neoplasia.Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD003296. doi: 10.1002/14651858.CD003296.pub3. Cochrane Database Syst Rev. 2013. PMID: 23740788 Free PMC article. Review.
-
The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial.Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):114-9. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12582020 Clinical Trial.
-
A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy.Invest New Drugs. 1986;4(3):241-4. doi: 10.1007/BF00179590. Invest New Drugs. 1986. PMID: 3818228
-
Retinoids for preventing the progression of cervical intra-epithelial neoplasia.Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003296. doi: 10.1002/14651858.CD003296.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2013 Jun 06;(6):CD003296. doi: 10.1002/14651858.CD003296.pub3. PMID: 17943787 Updated. Review.
Cited by
-
The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancer.Front Oncol. 2024 Sep 11;14:1453934. doi: 10.3389/fonc.2024.1453934. eCollection 2024. Front Oncol. 2024. PMID: 39323992 Free PMC article.
-
Retinoids: Molecular Aspects and Treatment in Premalignant Lesions and Cervical Cancer.Cancer Control. 2024 Jan-Dec;31:10732748241279514. doi: 10.1177/10732748241279514. Cancer Control. 2024. PMID: 39163121 Free PMC article. Review.
-
Phytochemicals in Cancer Treatment and Cancer Prevention-Review on Epidemiological Data and Clinical Trials.Nutrients. 2023 Apr 14;15(8):1896. doi: 10.3390/nu15081896. Nutrients. 2023. PMID: 37111115 Free PMC article. Review.
-
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.Nat Commun. 2020 Aug 26;11(1):4265. doi: 10.1038/s41467-020-18042-2. Nat Commun. 2020. PMID: 32848154 Free PMC article. Review.
-
Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2-3: A narrative review.Gynecol Oncol Rep. 2020 Jul 2;33:100608. doi: 10.1016/j.gore.2020.100608. eCollection 2020 Aug. Gynecol Oncol Rep. 2020. PMID: 32685652 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
